A J Kivitz

Summary

Affiliation: St. John's Mercy Medical Center
Country: USA

Publications

  1. ncbi request reprint Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial
    Alan J Kivitz
    Altoona Center for Clinical Research, Duncansville, Pennsylvania, USA
    J Am Geriatr Soc 52:666-74. 2004
  2. ncbi request reprint Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trial
    Alan Kivitz
    Altoona Center for Clinical Research, Duncansville, Pennsylvania 16635, USA
    Clin Ther 28:1619-29. 2006
  3. ncbi request reprint HUMIRA pen: a novel autoinjection device for subcutaneous injection of the fully human monoclonal antibody adalimumab
    Alan Kivitz
    Altoona Center for Clinical Research, 1125 Old Route 220 North, Duncansville, PA 16635, USA
    Expert Rev Med Devices 4:109-16. 2007
  4. doi request reprint Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies
    Hal M Hoffman
    Division of Rheumatology and Allergy Immunology, University of California at San Diego, La Jolla, CA 92093 0635, USA
    Arthritis Rheum 58:2443-52. 2008
  5. ncbi request reprint Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip
    A J Kivitz
    Altoona Center for Clinical Research, Altoona, PA, USA
    J Int Med Res 29:467-79. 2001
  6. ncbi request reprint A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis
    Alan J Kivitz
    Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, USA
    Semin Arthritis Rheum 37:164-73. 2007
  7. doi request reprint Comparison of the effectiveness and tolerability of lidocaine patch 5% versus celecoxib for osteoarthritis-related knee pain: post hoc analysis of a 12 week, prospective, randomized, active-controlled, open-label, parallel-group trial in adults
    Alan Kivitz
    Altoona Center for Clinical Research, 1125 Old Route 220 North, Duncansville, PA 16635, USA
    Clin Ther 30:2366-77. 2008
  8. ncbi request reprint Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis
    A J Kivitz
    Altoona Center for Clinical Research, Duncansville, PA, USA
    Aliment Pharmacol Ther 19:1189-98. 2004
  9. ncbi request reprint Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy
    Mark C Genovese
    Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, California 94304, USA
    J Rheumatol 34:1040-50. 2007
  10. ncbi request reprint A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis
    John D Bradley
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Rheumatol 32:417-23. 2005

Detail Information

Publications17

  1. ncbi request reprint Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial
    Alan J Kivitz
    Altoona Center for Clinical Research, Duncansville, Pennsylvania, USA
    J Am Geriatr Soc 52:666-74. 2004
    ..To evaluate the use of starting doses of rofecoxib and nabumetone in patients with osteoarthritis (OA) of the knee...
  2. ncbi request reprint Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trial
    Alan Kivitz
    Altoona Center for Clinical Research, Duncansville, Pennsylvania 16635, USA
    Clin Ther 28:1619-29. 2006
    ....
  3. ncbi request reprint HUMIRA pen: a novel autoinjection device for subcutaneous injection of the fully human monoclonal antibody adalimumab
    Alan Kivitz
    Altoona Center for Clinical Research, 1125 Old Route 220 North, Duncansville, PA 16635, USA
    Expert Rev Med Devices 4:109-16. 2007
    ..The adalimumab Pen offers these benefits and recent evidence indicates that patients overwhelmingly prefer the adalimumab Pen to the prefilled syringe...
  4. doi request reprint Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies
    Hal M Hoffman
    Division of Rheumatology and Allergy Immunology, University of California at San Diego, La Jolla, CA 92093 0635, USA
    Arthritis Rheum 58:2443-52. 2008
    ....
  5. ncbi request reprint Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip
    A J Kivitz
    Altoona Center for Clinical Research, Altoona, PA, USA
    J Int Med Res 29:467-79. 2001
    ..Both drugs were generally well tolerated. Celecoxib at a dose of 200 mg/day is as effective as a standard therapeutic dose of the conventional NSAID, naproxen, in reducing the pain associated with OA of the hip...
  6. ncbi request reprint A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis
    Alan J Kivitz
    Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, USA
    Semin Arthritis Rheum 37:164-73. 2007
    ..To evaluate the efficacy of the cyclooxygenase-2 selective inhibitor celecoxib in treating patients with psoriatic arthritis (PsA) in flare...
  7. doi request reprint Comparison of the effectiveness and tolerability of lidocaine patch 5% versus celecoxib for osteoarthritis-related knee pain: post hoc analysis of a 12 week, prospective, randomized, active-controlled, open-label, parallel-group trial in adults
    Alan Kivitz
    Altoona Center for Clinical Research, 1125 Old Route 220 North, Duncansville, PA 16635, USA
    Clin Ther 30:2366-77. 2008
    ..Cyclooxygenase-2 (COX-2) selective inhibitors and nonselective NSAIDs are commonly used to treat osteoarthritis (OA) of the knee...
  8. ncbi request reprint Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis
    A J Kivitz
    Altoona Center for Clinical Research, Duncansville, PA, USA
    Aliment Pharmacol Ther 19:1189-98. 2004
    ..Lumiracoxib (Prexige; Novartis Pharma AG, Basel, Switzerland) is a cyclooxygenase-2 selective inhibitor associated with improved gastrointestinal safety compared with nonsteroidal anti-inflammatory drugs, in patients with osteoarthritis...
  9. ncbi request reprint Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy
    Mark C Genovese
    Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, California 94304, USA
    J Rheumatol 34:1040-50. 2007
    ..To demonstrate the safety and efficacy of adalimumab for the treatment of active psoriatic arthritis (PsA) in patients with an inadequate response to disease modifying antirheumatic drugs (DMARD)...
  10. ncbi request reprint A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis
    John D Bradley
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Rheumatol 32:417-23. 2005
    ..To evaluate the efficacy and safety of a selective inhibitor of secretory phospholipase (sPLA2), LY333013, in the treatment of rheumatoid arthritis (RA)...
  11. ncbi request reprint Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab
    Jeffrey L Kaine
    Sarasota Arthritis Research Center, Sarasota, Florida 34239, USA
    J Rheumatol 34:272-9. 2007
    ..This study compared the immunogenicity of influenza and pneumococcal vaccines in adult patients with rheumatoid arthritis (RA) receiving adalimumab or placebo...
  12. ncbi request reprint Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, Washington 98104, USA
    Arthritis Rheum 50:2264-72. 2004
    ..In this study, we further evaluated the safety, efficacy, and effect on radiographic progression of etanercept in patients with PsA...
  13. ncbi request reprint A comparison of valdecoxib and naproxen in the treatment of rheumatoid arthritis symptoms
    Gary W Williams
    Department of Medicine, Scripps Clinic, La Jolla, California 92037, USA
    Clin Ther 28:204-21. 2006
    ..The overall safety and tolerability profiles of valdecoxib and naproxen were also compared...
  14. ncbi request reprint Pain management in osteoarthritis: a focus on onset of efficacy--a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials
    Wendy P Battisti
    Merck and Co, Inc, West Point, Pennsylvania 19486, USA
    J Pain 5:511-20. 2004
    ..5 mg (P = .01) compared with nabumetone. Rofecoxib treatment, with its faster onset of OA efficacy and lower rates of related discontinuations, might provide efficacy advantages in the treatment of OA pain...
  15. ncbi request reprint Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, Washington 98104, USA
    J Rheumatol 33:712-21. 2006
    ..Clinical and radiographic responses were evaluated in patients with psoriatic arthritis (PsA) treated for up to 2 years with etanercept...
  16. ncbi request reprint Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of Osteoarthritis of the knee
    Thomas J Schnitzer
    Northwestern Center for Clinical Research, Chicago, Illinois 60611, USA
    Arthritis Rheum 53:827-37. 2005
    ....
  17. ncbi request reprint Denosumab in postmenopausal women with low bone mineral density
    Michael R McClung
    Providence Portland Medical Center, Portland, Oreg, USA
    N Engl J Med 354:821-31. 2006
    ..The fully human monoclonal antibody denosumab (formerly known as AMG 162) binds RANKL with high affinity and specificity and inhibits RANKL action...